These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19291787)

  • 1. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
    Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
    Crisan D; Grigorescu M; Crisan N; Craciun R; Lupsor M; Radu C; Grigorescu MD; Suciu A; Epure F; Avram L; Leach N
    J Physiol Pharmacol; 2019 Aug; 70(4):. PubMed ID: 31642820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.
    Nirei K; Matsumura H; Kumakawa M; Matsumoto N; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
    Int J Med Sci; 2017; 14(1):45-52. PubMed ID: 28138308
    [No Abstract]   [Full Text] [Related]  

  • 8. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
    Fontana RJ; Litman HJ; Dienstag JL; Bonkovsky HL; Su G; Sterling RK; Lok AS;
    Liver Int; 2012 Apr; 32(4):665-74. PubMed ID: 22103814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
    Stättermayer AF; Rutter K; Beinhardt S; Wrba F; Scherzer TM; Strasser M; Hofer H; Steindl-Munda P; Trauner M; Ferenci P
    Liver Int; 2014 Mar; 34(3):388-95. PubMed ID: 23870067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
    Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
    Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
    Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
    Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
    Freedman ND; Everhart JE; Lindsay KL; Ghany MG; Curto TM; Shiffman ML; Lee WM; Lok AS; Di Bisceglie AM; Bonkovsky HL; Hoefs JC; Dienstag JL; Morishima C; Abnet CC; Sinha R;
    Hepatology; 2009 Nov; 50(5):1360-9. PubMed ID: 19676128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
    Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
    Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
    Dultz G; Seelhof M; Herrmann E; Welker MW; Friedrich-Rust M; Teuber G; Kronenberger B; von Wagner M; Vermehren J; Sarrazin C; Zeuzem S; Hofmann WP
    PLoS One; 2013; 8(8):e71262. PubMed ID: 23936497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
    Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
    Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
    Iwasa M; Hara N; Miyachi H; Tanaka H; Takeo M; Fujita N; Kobayashi Y; Kojima Y; Kaito M; Takei Y
    J Viral Hepat; 2009 Oct; 16(10):716-23. PubMed ID: 19302338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
    Werling K; Schaff Z; Dinya E; Tulassay Z
    Pathol Oncol Res; 2010 Jun; 16(2):149-57. PubMed ID: 19757200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.